BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/5/2022 1:22:29 AM | Browse: 226 | Download: 311
 |
Received |
|
2022-01-06 16:00 |
|
Peer-Review Started |
|
2022-01-06 16:01 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-03-10 22:23 |
|
Revised |
|
2022-04-10 19:48 |
|
Second Decision |
|
2022-05-10 02:52 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-05-14 07:29 |
|
Articles in Press |
|
2022-05-14 07:29 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-06-17 01:58 |
|
Publish the Manuscript Online |
|
2022-07-05 01:22 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Opinion Review |
| Article Title |
Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Maja Cigrovski Berkovic, Tanja Rezic, Ines Bilic-Curcic and Anna Mrzljak |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Anna Mrzljak, PhD, Adjunct Associate Professor, Department of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Kispaticeva ul 12, Zagreb 10000, Croatia. anna.mrzljak@gmail.com |
| Key Words |
Semaglutide; Non-alcoholic fatty liver disease; Glucagon-like peptide-1 receptor agonists; Metabolically associated fatty liver disease |
| Core Tip |
The pathogenesis of metabolically associated fatty liver disease (MAFLD) is closely interrelated to type 2 diabetes mellitus (T2DM), with insulin resistance and hyperinsulinemia as key characteristics. Glucagon-like peptide-1 receptor agonists have a favorable effect on glycemic management and weight loss in T2DM patients. Semaglutide is an especially interesting agent with favorable metabolic actions in patients sharing T2DM and MAFLD (but also sole MAFLD) phenotype, available in injectable and oral formulation, thus more attractive for a broader spectrum of patients. |
| Publish Date |
2022-07-05 01:22 |
| Citation |
Cigrovski Berkovic M, Rezic T, Bilic-Curcic I, Mrzljak A. Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum? World J Clin Cases 2022; 10(20): 6759-6768 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i20/6759.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i20.6759 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
